Skip to main content
CJC-1295 Online

An online reading room for the CJC-1295 research record — the GHRH analog, its DAC variant, and the pharmacokinetics that separate them.

01 / people and animals in studies

CJC-1295 Tests Found Hormone Rises, Not Lasting Benefits

Blood tests measured hormone rises; mouse studies measured growth. Stage 1 tested early safety. Stage 2 tested possible benefit, but stopped. The findings differ from reports about ipamorelin.

CJC-1295 Starts Hormone Release in a Gland Below the Brain

Researchers measured growth hormone after CJC-1295 entered the blood. The substance prompts the small gland beneath your brain. Cells in that gland start making and releasing growth hormone. The hormone enters the blood in bursts [1]. The liver makes another growth-related hormone after growth hormone rises [3].

The hormones come from your own gland and liver.

Four changes slow breakdown inside the body. Researchers tested a hormone with one changed building block in healthy men. The changed starting hormone stayed in blood longer than the unchanged hormone. The men also cleared the changed hormone more slowly [2]. Attachment to blood protein gives the linked form added protection. The joined substance weighs about 67 kilodaltons. Kilodaltons measure tiny weights beyond an ordinary scale's reach. The joined substance is too large for kidney filtering. Joining also shields the substance from breakdown [1]. The linked form stays in healthy adults' blood for several days [3].

Remaining in blood longer doesn't prove better health for you.

CJC-1295 Forms Had Different Shot Timing in Research

Both forms have four changed protein building blocks. The extra link, called DAC, sets the linked form apart. The link attaches to protein found naturally in blood. Joining keeps the substance from leaving blood so quickly.

In 2006, the Teichman study tested linked CJC-1295 in healthy adults. After one shot, growth hormone remained raised six days, sometimes longer. The liver hormone stayed high between nine and eleven days. The high liver hormone level lasted through 28 days with repeated shots [3]. Stage 1 early safety tests and stage 2 benefit tests gave shots once or twice weekly [3][9].

These study schedules don't establish safe timing for your care.

Without DAC, CJC-1295 has the name modified GRF. Half the unlinked form leaves blood in roughly 30 minutes [10]. The rise in growth hormone is briefer with this form. The four changes still help the unlinked form resist breakdown. Research accounts describe daily skin shots, sometimes given before bed. Those accounts aimed to follow hormone bursts from the gland [10].

The Linked Form Remains After Much of the Unlinked Form Has Left

A blood protein holds on to the linked CJC-1295 form. Half the linked form leaves blood in about 8 days. Half the unlinked form leaves in about 30 minutes [1][10]. The unlinked form briefly raises growth hormone. The linked form gives a lasting rise, as its makers intended.

CJC-1295 Left the Normal Timing of Bursts Intact

In 2006, Ionescu found the usual hormone bursts continued. CJC-1295 continued prompting the gland between study shots. Half the linked form remains in blood about 8 days. The body's own starting hormone disappears within minutes. Even with the lasting effect, burst size and spacing stayed unchanged [4].

CJC-1295 DAC Attaches After a Shot Reaches Blood

DAC names the extra link on the longer-lasting form. After a skin shot, the added link attaches to blood protein. Half then leaves blood in about 8 days [1]. The joined substance and protein weigh 67 kilodaltons, a tiny-weight measure. The joined substance is too large for kidney filtering.

CJC-1295 Without DAC Has a Briefer Effect on Hormone Release

Unlinked CJC-1295 retains four changes that slow its breakdown [10]. Those changes don't attach the substance to a blood protein. Half the unlinked form leaves blood in about 30 minutes. Research accounts describe daily skin shots, sometimes just before bed. Growth hormone rises in briefer bursts with the unlinked form.

CJC-1295 Forms Had Different Shot Timing in Research

Lasting Changes in Muscle and Fat Have Not Been Shown

Healthy adults had higher growth hormone after one CJC-1295 skin shot. The rise lasted six days, sometimes longer [3]. The liver hormone remained high between nine and eleven days [3]. Repeated shots kept that liver hormone raised through 28 days [3]. A second study measured a rise of 46% in average growth hormone. Between bursts, levels rose. Burst size and spacing stayed unchanged [4]. Mice missing the starting hormone received daily 2 microgram shots. Micrograms measure tiny weights. After five weeks, those mice reached normal length and weight [8].

A human hormone rise and a mouse's growth are different findings.

Completed human tests haven't shown lasting changes in muscle or fat. Safety over years is unknown, as are direct testosterone effects [3]. Testosterone belongs to the sex hormones. A stage 2 trial studied people living with HIV. This virus can weaken your immune system. The trial tested fat well inside the patients' bellies. The trial stopped before showing whether the substance reduced that fat [5][9].

Human Studies Raised Hormones; Sick Mice Grew to Normal Size

In 2006, Teichman's healthy adult volunteers received CJC-1295-DAC during stage 1. This first stage tests early human safety. Adults had skin shots containing progressively larger amounts. After one shot, higher growth hormone levels lasted six days, sometimes longer. The liver hormone stayed high between nine and eleven days. No serious unwanted reactions were reported [3]. In 2006, Ionescu tested 60 or 90 micrograms for every kilogram the person weighed. Micrograms measure tiny weights; kilograms measure body weight. The liver hormone rose 45%, and average growth hormone rose 46%. Between bursts, the hormone level was higher. Burst timing and size stayed unchanged [4].

Neither study established lasting health gains for you.

In 2006, Alba tested mice missing the body's starting hormone. Daily shots of 2 micrograms restored normal growth over five weeks. Shots spaced 48 hours apart or at 72-hour gaps worked less well. Healthy people don't have the mice's disorder [8].

Stage 2 tests possible benefit; stage 3 uses larger groups. Neither stage has published proof of benefit from this substance. The 2006 stage 2 trial stopped without posting results. The trial concerned abnormal fat buildup and loss in patients [9].

Human Studies Raised Hormones; Sick Mice Grew to Normal Size

The 2006 Stage 2 Trial Ended Without Answering Its Health Question

In December 2005, ConjuChem began a stage 2 CJC-1295 trial. This stage tests possible benefit beyond early safety checks. The patients lived with HIV, a virus that weakens immunity. The trial tested fat deep inside their bellies. Across several centers, 192 patients entered groups by chance. Some received the substance; others received placebo, a shot without it. Patients receiving CJC-1295 had progressively larger weekly skin shots. One group progressed through 60, 90, 120 micrograms for every kilogram the person weighed. The other progressed through 60, 120, 240 micrograms for every kilogram [9]. Micrograms measure tiny weights; kilograms measure the person's body weight.

On 17 July 2006, a participant's death stopped the trial [5].

A man in Argentina died after his eleventh weekly shot. He had a heart attack shortly after that shot. The investigator suspected heart artery disease without earlier warning symptoms. A fatty deposit inside an artery had torn open. The company considered a direct link to CJC-1295 unlikely, but ended development [5]. ClinicalTrials.gov lists the trial as stopped, without posted results [9].

Related substances left smaller heart scars in animal tests after heart attacks. The damaged hearts also recovered a more normal shape [11]. This helped explain the view taken about the man's death in 2006. Animal findings can't prove what caused his heart attack. No replacement stage 2 trial opened during the next 19 years.

CJC-1295 and Ipamorelin Reach Hormone-Making Cells in Different Ways

CJC-1295 copies the natural starting hormone for growth hormone release. Ipamorelin copies an effect of the hunger hormone, called ghrelin [12]. The substances act at different points on hormone-making cells. Both substances prompt more growth hormone to come from those cells.

Separate starting steps explain researchers' interest in the combined substances.

In animals, ipamorelin strongly prompted growth hormone release. Several other hormones didn't rise greatly at the high amounts tested [12]. These included cortisol, a stress hormone, and prolactin, which helps milk production. This difference explains interest in combining ipamorelin with CJC-1295. CJC-1295 raises the level of growth hormone release between bursts. Ipamorelin adds a brief burst through a different starting step [12].

CJC-1295 and Ipamorelin Produced a Larger Rise Together in Tests

CJC-1295 copies the natural starting hormone for growth hormone release. Ipamorelin acts where the body's hunger hormone acts [12]. The substances reach hormone-making cells through different starting points. Early tests found growth hormone rose more with both substances together [12].

CJC-1295 With Ipamorelin Starts Two Routes to Hormone Release

Researchers study the pair because each substance starts release differently. CJC-1295 raises growth hormone release between bursts from the gland. Ipamorelin adds a burst without raising cortisol or prolactin [12]. Cortisol is a stress hormone; prolactin helps with milk production. Starting both steps increases release instead of repeating one step.

CJC-1295 and Ipamorelin Reach Hormone-Making Cells in Different Ways

Blood Tests Changed Before Any Claimed Muscle or Fat Change

Growth hormone rose within hours of a CJC-1295-DAC skin shot. Growth hormone stayed high with the linked form over six days, sometimes longer [3]. The liver hormone also rose after the study shot. The liver hormone stayed high between nine and eleven days. With repeated shots, the high liver hormone level lasted through 28 days [3].

The blood tests didn't show less fat or more muscle.

Completed human trials haven't measured those lasting changes. The stage 2 trial planned to measure benefit stopped before answering that question [9]. People trying the substance outside controlled studies report changes they have noticed. These are personal accounts, without a trial's comparison against placebo. Placebo is a treatment without the substance being tested. Trials haven't checked these accounts or the changes people describe. Those reports don't establish a health result that you can expect.